94 related articles for article (PubMed ID: 25822574)
1. Prostate cancer screening: contrasting trends.
Eisinger F; Morère JF; Touboul C; Pivot X; Coscas Y; Blay JY; Lhomel C; Viguier J
Cancer Causes Control; 2015 Jun; 26(6):949-52. PubMed ID: 25822574
[TBL] [Abstract][Full Text] [Related]
2. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
3. Cancer screening in France: third edition of the EDIFICE survey.
Viguier J; Morère JF; Touboul C; Coscas Y; Blay JY; Lhomel C; Pivot X; Eisinger F
Eur J Cancer Prev; 2015 Jun; 24 Suppl():S68-72. PubMed ID: 26016790
[TBL] [Abstract][Full Text] [Related]
4. Screening for prostate cancer: growth without control.
Eisinger F; Blay JY; Pivot X; Morère JF; Coscas Y; Calazel-Benque A; Roussel C; Viguier J
Eur J Cancer Prev; 2011 Jan; 20 Suppl 1():S33-5. PubMed ID: 21245678
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities.
Guessous I; Cullati S; Fedewa SA; Burton-Jeangros C; Courvoisier DS; Manor O; Bouchardy C
Prev Med; 2016 Jan; 82():83-91. PubMed ID: 26582208
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997.
McDavid K; Melnik TA; Derderian H
Prev Med; 2000 Sep; 31(3):195-202. PubMed ID: 10964632
[TBL] [Abstract][Full Text] [Related]
7. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
[TBL] [Abstract][Full Text] [Related]
8. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
9. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
11. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
12. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
13. Predictors of prostate cancer screening among health fair participants.
Chiu BC; Anderson JR; Corbin D
Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522
[TBL] [Abstract][Full Text] [Related]
14. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
[TBL] [Abstract][Full Text] [Related]
15. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
16. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
17. [Consensus of prostate cancer screening].
Prostate Cancer Working Group of Genitourinary Cancer Committee in Chinese Anti-Cancer Association
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):340-342. PubMed ID: 28464572
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer screening controversy: too much or not enough?
Pivot X; Viguier J; Touboul C; Morère JF; Blay JY; Coscas Y; Lhomel C; Eisinger F
Eur J Cancer Prev; 2015 Jun; 24 Suppl():S73-6. PubMed ID: 26016791
[TBL] [Abstract][Full Text] [Related]
19. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
20. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
